X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ART0380 is a potent, selective, oral inhibitor of ATR, a master regulator of DNA replication stress response. It is being developed as an anti-cancer agent for cancers that harbor defects in DNA repair.
Lead Product(s): ART0380,Gemcitabine
Therapeutic Area: Oncology Product Name: ART0380
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
ART4215 is first selective, oral, small molecule inhibitor of Polθ polymerase domain to enter clinic. Polθ, a DNA polymerase, is a tumor-specific DDR target involved in MMEJ that is overexpressed in many tumors and found in low levels in healthy tissue.
Lead Product(s): ART4215,Talazoparib
Therapeutic Area: Oncology Product Name: ART4215
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
ART0380, an ataxia telangiectasia, and Rad3-related (“ATR”) Inhibitor, demonstrated a predictable safety profile and no unexpected safety findings supported by data from over 35 patients in Phase 1a dose escalation.
Lead Product(s): ART0380,Gemcitabine,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ART0380
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Financing supports expansion of potentially best-in-class ATR inhibitor and first-in-class highly selective Polθ inhibitor programs by enabling clinical development in multiple tumor settings and biological backgrounds of single agent and combination therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 27, 2021
Details:
Company’s approach to developing a potential first-in-class Polθ inhibitor, which demonstrated potent, selective Polθ inhibition, BRCA-gene synthetic lethality in a potentially PARP-resistant setting, and PARP inhibitor synergy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
Under the three-year collaboration, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, and receive worldwide rights on these targets to be utilized with its RLT’s.
Lead Product(s): Radioligand Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,320.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration April 07, 2021
Details:
Under the terms of the agreement, the companies will leverage Artios’s proprietary nuclease targeting discovery platform to jointly identify multiple synthetic lethal targets for precision oncology drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $6,910.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration December 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
